Recent News

• 04.08.2025 - Stifel Targeted Oncology Forum
• 04.08.2025 - Stifel Targeted Oncology Forum
• 03.11.2025 - Leerink's Global Healthcare Conference 2025
• 03.11.2025 - Leerink's Global Healthcare Conference 2025
• 03.10.2025 - OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
• 03.10.2025 - OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
• 03.04.2025 - OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences
• 03.04.2025 - OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences
• 02.03.2025 - JonesTrading Virtual Precision Medicine Symposium

Recent Filings

• 03.24.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 03.21.2025 - EFFECT Notice of Effectiveness
• 03.20.2025 - POS AM Post-Effective amendments for registration statement
• 03.10.2025 - EX-99.1 EX-99.1
• 03.10.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 03.10.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.10.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.10.2025 - 8-K Current report
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors